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Abstract.  The adhesion and motility of tumor cells on 
basement membranes is a central  consideration  in tu- 
mor cell invasion and metastasis.  Basement membrane 
type IV collagen directly promotes the adhesion and 
migration  of various tumor cell types in vitro. Our 
previous studies demonstrated that tumor cells adhered 
and spread on surfaces coated with intact type IV col- 
lage.n or either of the two major enzymatically purified 
domains of this protein.  Only one of these major do- 
mains,  the pepsin-generated major triple helical  frag- 
ment,  also supported tumor cell motility in vitro,  im- 
plicating the involvement of the major triple helical 
region in type IV collagen-mediated tumor cell inva- 
sion in vivo. The present studies extend our previous 
observations using a synthetic peptide approach.  A 
peptide, designated IV-H1, was derived from a con- 
tinuous collagenous region of the major triple helical 
domain of the human al(IV) chain.  This peptide, 
which has the sequence GVKGDKGNPGWPGAE di- 
rectly supported the adhesion,  spreading,  and motility 
of the highly metastatic K1735 M4 murine melanoma 
cell line,  as well as the adhesion and spreading of 
other cell types, in a concentration-dependent  manner 
in vitro.  Furthermore,  excess soluble peptide IV-H1, 
or polyclonal antibodies directed against peptide 
IV-HI,  inhibited type IV collagen-mediated melanoma 
cell adhesion,  spreading,  and motility, but had no 
effect on these cellular responses to type I collagen. 
The full complement of cell adhesion,  spreading,  and 
motility promoting activities was dependent upon the 
preservation of the three prolyl residues in the peptide 
IV-H1  sequence.  These studies indicate that peptide 
IV-H1  represents a cell-specific adhesion,  spreading, 
and motility promoting domain that is active within 
the type IV collagen molecule. 
I 
N light of the involvement of tumor cell adhesion and mo- 
tility  in the process of basement membrane (BM) ~ in- 
vasion (Liotta,  1977),  it appears that type IV collagen 
may play a role in the invasion of BM by various tumor types. 
In vitro, BM type IV collagen  promotes the adhesion  and 
motility of various normal and transformed  cell types (Kur- 
kinen  et al.,  1984; Aumailley  and Timpl,  1986; Tomaselli 
et al.,  1988;  Herbst et al.,  1988; Chelberg et al.,  1989). 
In our previous studies  using the highly  metastatic murine 
melanoma cell line K1735 M4 (Fidler et al., 1981), the cells 
adhered and spread on surfaces coated with intact  type IV 
collagen,  as  well  as  to  surfaces coated  with  the  isolated 
globular collagenase-generated  major  noncollagenous  do- 
main of type IV collagen (NCI) or the purified pepsin-gener- 
ated major triple helical  fragment  (p-IV),  which lacks the 
NCI domain.  However, motile behavior was observed only 
in response to the helical  p-IV fragment (Chelberg et al., 
1989). These findings are consistent with the involvement of 
multiple.distinct  regions  on the type IV collagen  molecule 
!.  Abbreviations  used  in  this  paper:  BM,  basement  membrane;  FN, 
fibronectin; KLH, keyhole limpet hemocyanin; NCI, collagenase-generated 
major noncollagenous domain of type IV collagen; p-IV, pepsin-generated 
major triple helical  fragment of type IV collagen. 
in cell adhesion,  spreading,  and motility  (Chelberg et al., 
1989), and suggest that the p-IV fragment may be important 
for tumor cell  invasion of BM. 
To characterize  further the molecular basis of the cellular 
responses  promoted  by the p-IV  fragment,  a series of syn- 
thetic peptides derived from the triple helical region of human 
type IV collagen was screened for the ability to promote the 
adhesion and spreading of the M4 murine melanoma cell line 
in vitro. The present studies provide evidence that the pep- 
tide  designated  IV-H1  (having  the  amino  acid  sequence 
GVKGDKGNPGWPGAP2; residues 1263-1277)  represents 
a specific cell adhesion,  spreading,  and motility promoting 
domain within the major triple helical region of type IV col- 
lagen.  Peptide IV-HI promoted the adhesion and spreading 
of various cell types, and was a potent attractant  for M4 mel- 
anoma cell motility. Preservation  of the prolyl residues ap- 
pears to be necessary for the full complement of adhesion, 
spreading, and motility promoting activities of the IV-H1 se- 
quence.  The data indicate  that the activity  associated with 
the IV-H1 sequence is active within,  and specific to, type IV 
2. A, alanine; D, aspartate;  E, glutamate; G, glycine; K, lysine; N, aspara- 
gine; E proline; Q, glutamine; R, arginine; S, serine; V, valine; W, trypto- 
phan;  Y, tyrosine. 
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(or polyclonal antibodies generated against peptide IV-HI), 
inhibited type IV collagen-mediated (but not type I collagen- 
mediated) melanoma cell adhesion, spreading, and motility. 
These studies indicate that peptide IV-H1 represents a ceil- 
specific adhesion, spreading, and motility promoting domain 
that is active within the type IV collagen molecule. 
Materials and Methods 
Cell Culture 
The highly metastatic murine melanoma cell line, termed K1735 M4, was 
a generous gift from Dr. I. J. Fidler (M. D. Anderson, Houston, TX). This 
cell line was routinely maintained in DME media (Sigma Chemical Co., 
St. Louis, MO) supplemented with 10% calf serum (CS). Cells were pas- 
saged twice weekly with trypsin as previously described (Chelberg et al., 
1989), and care was taken to limit the number of in vitro passages to 8 to 
minimize phenotypic drift. Dr. Fidler also provided the highly metastatic 
human melanoma cell line A375 SM, which was maintained in MEM with 
added vitamins and 10% FBS; and the fibrosarcoma cell line UV2237 MM, 
which was maintained in DME with 10% FBS. Other cell lines studied in- 
clude: the C6 rat glioma cell line (No.  CCLIff'/; American Type Culture 
Collection [ATCC], Roekville, MD), which was maintained in DME plus 
10% CS; the SCC9 human squamous carcinoma cell line (No. CRL1629; 
ATCC), which was maintained in a 1:1 solution of DME and HAM FI2 con- 
taining 10% FBS; the 1365 and B104 murine neuroblastoma cell lines that 
were a generous gift from Dr. David Schubert at the Sulk Institute (Schubert 
et al., 1974) and maintained in FI2H media with supplements; and bovine 
aortic endothelial ceils, which were isolated and maintained as described 
previously (Herbst et al.,  1988). 
Protein Purification and Preparation of Proteolytic 
Fragments of l)~e IV Collagen 
Type IV collagen was extracted from the Englebreth Holm Swarm sarcoma 
grown in lathyritic mice according to a modification of the method by Klein- 
man et al.  (1982) as previously described (Herhst et al.,  1988; Chalberg 
et al., 1989). Type IV collagen purified by DEAE anion exchange chroma- 
tography was subjected to ultracentrifugation at 110,000 g  for 90 rain to 
clear aggregates >50S.  The supematant was decanted and stored in 2  M 
guanidine containing 2 mM DTT at 4"C until needed. The concentration 
of type IV collagen was determined spectrophotometrically as previously 
described (Waddell,  1956; Chelborg et al.,  1989). Type I collagen (Vitro- 
gen) was obtained from the CoUagen Corporation (Pale Alto, CA). Human 
plasma fibronectin (FN) was purified by sequential ion exchange and gelatin 
affinity chromatography as described previously (McCarthy et al.,  1986). 
Peptide Synthesis and Characterization 
Peptides representing amino acid sequences from human type IV collagen 
or FN were synthesized using a peptide synthesizer (990; Beckman Instru- 
ments,  Inc.,  Pale  Alto,  CA),  either  by  Dr.  Robert  Wohlhueter  at  the 
Micrecbemical Facility of the University of Minnesota, or by Dr. Bianca 
Conti-Troneoni (University of Minnesota at St. Paul). The procedures used 
were based on the Merrifield solid phase system as described previously 
(Stewart and Young,  1984).  Lyophilized crude peptides were purified by 
preparative reverse-phase HPLC on a C-18 column, using an elution gra- 
diem of 0-60% acetonitfile with 0.1% trifluoroacetic acid in water. The pu- 
rity and composition of the peptides was verified by HPLC analysis of acid 
hydrolysates of the peptides. Peptides, including peptide IV-HI (GVKGDK- 
GNU)  and a variant of peptide IV-HI (G'VKGDKGNAGWAGAA, 
designated peptide IV-H1A), were synthesized from the sequence of the ma- 
jor triple helical domain of human type IV collagen (Table I). As an addi- 
tional control, an unrelated FN-derived peptide I (YEKPGSPPREVVPR- 
PRPGV  2,  McCarthy  et  al.,  1990)  was  studied.  Certain  peptides  were 
synthesized with a tyrosyl residue to the carboxy terminal end to allow ra- 
dioactive iodination of the peptide. 
lodination of  Peptides and Determination of  Binding 
El~iciency on Immulon 1 Plates 
Labeling of peptides with Nat251 was performed as described by McCona- 
Table L Type IV Collagen-derived Synthetic Peptides 
Peptide name  Peptide sequence*  Residue numberst 
Peptide  15 
Peptide  16 
Peptide  17 
Peptide  18 
IV-H1 
IV-HIA 
GPKGEPGKIVPLPG(Y)  634-647 
GLPGKPGSNDKVDMGSMKG(Y)  930-948 
GVPGKDGQAGQPGQP(Y)  975-989 
GEKGDKGLPGLD(Y)  1115-1126 
GVKGDKGNPGWPGAP(Y)  1263-1277 
GVKGDKGNAGWAGAA(Y) 
*  Using the single-letter amino acid code: A, alanine; D, aspartate; E, gluta- 
mate:  G,  glycine;  1.  isoleucine;  K,  lysine;  L,  leucine;  M,  methionine;  N, 
asparagine; P, proline; Q, glutamine; S, serine; V, valine; W, tryptophan. Each 
peptide contained a tyrosine residue (Y) at the carboxyl terminal end so that 
the peptides could be iodinated. 
Residue numbers assigned beginning with amino terminal end, based upon 
the sequence presented in Muthukumaran et al.  (1989). 
hey and Dixon (1980). Briefly, 0.1  mg of each peptide in NaHPO4 buffer 
(pH 7.2) was incubated for 2 rnin with 0.05 nag chloramine T and 0.5 mCi 
Nal25I (New England Nuclear, Boston, MA). The reaction was terminated 
by the addition of 0.2 mg of Na2S205. Free iodine was removed by reverse- 
phase chromatography using Sep-pak C-18 columns ONaters  Division of 
Millipore, Bedford, MA), from which the radiolabeled peptides were elnted 
with acetonitrile (50%) containing 0.1%  trifluoroacetic acid.  The labeled 
peptides were lyophilized and stored at -80°C until needed. The efficiency 
of peptide binding to the wells of 96-well polystyrene Immulon 1 plates (Dy- 
natech Laboratories Inc., Chantilly, VA) was determined by drying down 
100 #1 aliquots of radioiodinated peptides, which had been diluted in Voller's 
carbonate buffer to concentrations ranging from  1-10/~g/mi. To simulate 
binding conditions of the peptides in adhesion and spreading assays, the 
wells were then washed and incubated for 2 h with 150 #l/well of a 10 mg/ml 
solution of BSA in Voller's carbonate buffer. The wells were then washed 
and the amount of peptides bound to the surfaces was qnantitated by sohi- 
bilizing the peptides with 150/~l/well of 0.5 N NaOH containing 1% SDS. 
Bound radioactivity was quantitated in a gamma counter (1193; Tm Ana- 
lytic Inc.,  Elk Grove Village, IL). 
Generation and Purification of  Polyclonal Antibodies 
Polyclonal antibodies were generated against peptide IV-H1 coupled to key- 
hole limpet hemocyanin (KLH; Sigma Chemical Co., St. Louis, MO) using 
carbodiimide as a coupling agent, based on a procedure described previ- 
ously (Bauminger and Wilchek,  1980). Briefly, equal amounts (by weight) 
of peptide and KLH were solubilized in water and mixed with a 10-fold ex- 
cess (by weight) of 1-ethyl-3(3-dimethlyaminopropyl)-carbodiimide hydro- 
chloride (Sigma Chemical Co.) dissolved in water. New Zealand white rab- 
bits were immunized on the back by multiple subcutaneous injections of '~ 2 
rag/rabbit of peptide/KLH conjugate in complete Freund's adjuvant. Subse- 
quent biweekly boosts were given intramuscularly in incomplete Freund's 
adjuvant. Sera were collected 14 d after the fourth immunization, and tested 
by RIA for reactivity against uncoupled peptide, the protein of origin, and 
various other ligands. Immune sera were also prepared from rabbits im- 
munized with FN peptide I coupled to KLH as a control to confirm the spe- 
cificity of the antibody response for peptide IV-H1, rather than for the KLH. 
IgG was purified from normal rabbit sera and pooled immune sera by 
precipitation with a final concentration of 50 % ammonium sulfate overnight 
at 4°C.  The resolubilized precipitate was dialyzed against 0.035 M  NaCI 
in 0.025 M Tris, pH 8.8, and the IgG was purified by DEAE column chroma- 
tography as described previously (Skubitz et al.,  1987). Purity of the IgG 
was determined by SDS-PAGE.  Retained immunoreactivity of the purified 
IgG was verified by RIA (Skuhitz et al.,  1987). 
Assays  for Antibody Specificity 
Immune sera and purified antipeptide IV-H1 IgG were screened for spe- 
cificity by an indirect solid-phase RIA in 96-well polystyrene lmmulon I 
plates as described previously,  with minor modifications (Skubitz et al., 
1987).  Briefly, 50 #1 of proteins or peptides at various concentrations in 
Voller's carbonate buffer was added to each well and dried overnight at 
29°C.  The next day, 200/zl of PBS containing 5% BSA (fraction V, fatty 
acid free, Sigma Chemical Co.), 0.1% Triton X-100, and 0.02% NaN3 was 
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of this buffer, 100 #! of purified IgG at various dilutions in PBS containing 
5% BSA and 0.02%  NAN3, was added in triplicate and the wells were in- 
cubated I h at 37°C. After three washings with the above buffer, bound IgG 
was detected by the addition of 100 #i of 5 % BSA in PBS/NaN3 containing 
'x,100,000  cpm of 125I-Iabcled donkey IgG directed against rabbit Ig (sp  9 
act, 5 #Ci/#g; Amersham Corp., Arlington Heights, IL). After a 1-h incu-  • 
bation at 37°C, unbound antibody was removed  by washing. After an incu-  "0"1= 
bation with 100 #1 of  2 M NaOH for 15 rain at 60°C, the solubilized proteins 
were transferred to glass tubes and the radioactivity was measured in a 
gamma counter (1193;  Tm Analytic Inc.). 
Cell  Adhesion and Spreading  Assays 
Assays for cell adhesion and spreading were performed as previously de- 
scribed (Chelberg et al., 1989).  Briefly, subconfluent cultures of cells were 
radiolabeled overnight with 2 #Ci/ml [3H]thymidine. Before the adhesion 
assay,  cells were released from the culture flasks with 10 mM EDTA in 
Hanks media or, alternatively, in a trypsin solution (0.05%  trypsin with 
0.02 % EDTA) to confirm that cell adhesion did not require endogenous cell 
surface proteins that would be retained after EDTA treatment. Cells were 
then  washed  and  resuspended to  a  final  concentration of 4-5  ×  104 
cells/m] in DME supplemented with 20 mM Hepes and 10 mg/ml BSA. The 
cells remained viable (>95 %) after this procedure, based upon exclusion 
of trypan blue dye. 
Immulon 1 microtiter plates were prepared by drying down 100 #l/well 
of protein or peptide that had be~n diluted to various concentrations (1-500 
#g/ml) in Voller's carbonate buffer.  The relative abilities of the peptides to 
bind the plates was determined using radioiodinated peptides to be certain 
that any differences in cell adhesion or spreading were not due to differential 
binding to surfaces. Nonspecific cell adhesion to sites on the plastic was 
blocked by the use of a 10 mg/ml solution of  BSA in Voller's  carbonate buffer 
at 37°C for 2 h. The VolIer's/BSA solution was then aspirated and 5-6  × 
103 cells were added to each well in 150 #1 of adhesion media (DME con- 
taining 20 mM Hepes and 10 rag/m] BSA). The cells were incubated for 
30-40 rain at 37°C (or up to 90 min for certain assays), at which time cells 
were either visualized for spreading or harvested to determine adhesion. 
Adhesion was quantitated, after washing to remove nonadherent and weakly 
adherent cells, by solubilizing the cells with 150 #l/well of 0.5 N NaOH 
containing 1% SDS. Bound radioactivity was quantitated in a liquid scintil- 
lation counter (LS 3801; Beckman Instruments). Spreading determinations 
were made by two different individuals, in double blind studies by visualiz- 
ing at least 100 cells/well and calculating the percentage of spread cells. 
Each experiment was repeated a minimum of  three times, and within a given 
experiment, each experimental point was determined in triplicate. 
Inhibition of M4  melanoma cell adhesion and spreading on surfaces 
coated with type IV collagen was monitored in the presence of excess solu- 
ble peptides or polyclonal antibodies generated against synthetic peptides. 
In these assays, Immulon 1 plates were coated as described above for cell 
adhesion assays using concentrations of peptide IV-HI, type IV collagen, 
type I collagen, or FN (50 #g/ml of the peptide and 5 #g/m] of the intact 
proteins) which yielded half-maximal M4 melanoma cell adhesion in previ- 
ous dose-response  experiments. In the peptide inhibition studies, cells were 
preincubated for 20 min at 37°C in the presence (or absence) of various con- 
centrations of peptide IV-H1 to occupy the cell surface binding "receptors" 
recognizing these peptides. As controls, two other peptides were studied for 
the ability to inhibit collagen-mediated cell adhesion. The first, peptide 17 
(Table  I), was derived from type IV collagen and has a length and amino 
acid content similar to peptide IV-HI, but does not promote melanoma cell 
adhesion or spreading. The second, the FN-derived synthetic peptide I, pro- 
motes adhesion, spreading, and motility of the M4 melanoma cells (McCar- 
thy et al., 1990). In the antibody inhibition studies, the protein-coated sur- 
faces were incubated with various concentrations of purified normal rabbit 
IgG or purified lgG against peptid¢ IV-HI or peptide I to block the corre- 
sponding sequence within the surface-bound protein. Cells were then dis- 
pensed into the wells, in the continued presence of peptide or IgG, and in- 
cubated at 37°C for 30 rain. Spreading and adhesion determinations were 
quantitated as described above. 
Assay  for Cell Migration 
Peptide-mediated M4 melanoma cell motility was examined in 48-well mi- 
crocbemotaxis chambers (Neuro Probe, Inc., Cabin John, MD) equipped 
with 8-#m pore size polyvinylpyrrolidone-fre¢ polycarbonate filters by a 
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Figure 1. Melanoma cell adhesion and spreading in response to syn- 
thetic peptides. Surfaces were coated with 100 #l/well of various 
synthetic peptides ranging in concentration from  1-500  #g/ml  as 
described  in  Materials  and  Methods.  3H-Thymidine-labeled  M4 
melanoma cells were  added to wells coated  with  peptide IV-H1 
(o),  peptide  15  (==), peptide  17  (e),  or peptide  18  ([]).  (a)  Cell 
adhesion was quantitated and data are presented as the percent of 
added cells that were adherent. (b) Data are presented as the per- 
cent of added cells that were spread on surfaces coated with the pep- 
tides. All data represent the means of at least three experiments in 
which triplicate determinations were made  +  SEM. 
Chelberg et al.,  1989).  Briefly, peptidcs were diluted in Voller's carbonate 
buffer and added in triplicate 50 #1 aliquots to the lower wells of the cham- 
bers. The chambers were assembled with the filters in place and incubated 
overnight at 37°C to allow the peptides to adsorb to the lower surfaces of 
the filters. The filters were then washed and transferred to fresh chambers 
that contained only media (DME containing 20 mM Hepes, pH 7.4).  Cells 
were then added to the upper wells at 20,000/well in DME/Hepes media 
and incubated for 6 h at 37°C in a humidified CO2 chamber. Filters were 
then washed, fixed, and stained, and the number of cells that had migrat~ 
through the filters was quantitated using an Optomax Image Analysis Sys- 
tem, as previously described (Herbst et al., 1988;  Chelberg et al.,  1989). 
Each experiment was repeated a minimum of three times. 
The ability of peptide IV-HI or antipeptide IV-H1 polyclonal IgG to in- 
hibit type IV collagen-mediated  haptotactic motility was determined  by pre- 
coating filters on the underside with either type IV collagen or type I colla- 
gen in Voilcr's carbonate buffer as previously described (McCarthy et al., 
1989; Chelberg ct al., 1989).  The collagen coating concentration (5 #g/ml) 
was chosen based on the concentration which yielded half-maximal levels 
of cellular  motility (Chelberg et  al.,  1989).  As a  control for collagen 
specificity, certain studies included filters coated with a 5 #g/ml solution 
of FN, a potent inducer of M4 melanoma cell migration chemotactic activ- 
ity.  The inhibitory effect of peptidcs on cell motility was determined by 
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Peptide  IV-H 1" 
Species of  Type IV collagen 
Cell types  origin  Adhesion (~o)¢  Spreading  (~)  adhesion  (~) 
Group  1 
Group 2 
Group 3 
K1735  M4  Mouse  22.4  70  61.9 
melanoma 
A375  M  Human  16.3  20  50.3 
melanoma 
C6  Rat  35.9  82  100 
glioma 
BI04  Rat  18.5  20  18.6 
neuroblastoma 
Bovine aortic  Bovine  0.8  0  52.7 
endothelial cells 
Squamous cell  Human  1.9  0  39.6 
carcinoma 
UV 2237  Murine  1.1  0  7.9 
fibrosarcoma 
B65  Rat  4.6  0  7.7 
neuroblastoma 
* Surfaces  were coated with  100 #l/well of peptide  IV-HI or intact type IV collagen  at  100 ~g/ml in Voller's  carbonate  buffer. 
Percentage of input cells that adhered or spread as described in Materials  and Methods section.  Data is expressed as the average of three experiments;  each 
experiment  was performed in triplicate. 
preincubating the cells with increasing concentrations of the peptides for 
20 rain before the assay to allow for binding to cell surface receptors. Cells 
in the continued presence of peptides were then added to the upper wells 
of chambers containing the protein-coated filters. The inhibitory effect of 
antipeptide IV-H1 IgG on haptotaxis was delermined by incubation of the 
protein-coated filters for 20-30 min with antibody in the lower wells to bind 
(and thus block) the IV-H1  sequence within the type IV collagen molecule. 
Cells were then added to the upper wells and the assay proceeded as de- 
scribed above. In addition to IgG purified from normal rabbit sera, IgG 
generated against peptide I coupled to KLH was also used as a negative con- 
trol to confirm that antibodies generated against KLH did not contribute to 
the inhibitory effects of the antipeptide IV-HI IgG. 
Results 
Melanoma Cell Adhesion and Spreading on 
Peptide IV-H1 
A  number of type IV  collagen-derived synthetic peptides 
were  screened  for the  ability to  promote melanoma cell 
adhesion (Table I). As described previously (Koliakos et al., 
1989),  17 peptides were initially selected for synthesis from 
the published sequence of the major triple helical region of 
the od(IV) chain based upon their potential to bind heparin, 
as a model for glycosaminoglycan  binding. The criteria used 
to select the sequences to be synthesized included the pres- 
ence of the positively charged amino acid residues arginine 
and lysine, as well as the presence or absence of discontinui- 
ties of the triple helical motif. Although the charges of these 
peptides were potentially predictive of heparin binding abili- 
ties, only a  few of the peptides actually did bind heparin 
(these peptides have been extensively characterized; Koliakos 
et al., 1989).  In the present study, several of those peptides 
that did not bind heparin were screened for the ability to pro- 
mote the adhesion of melanoma cells, assuming that the pro- 
motion of cell adhesion by these peptides would likely in- 
volve a mechanism(s) distinct from binding a cell surface 
glycosaminoglycan. Only one of the peptides studied (desig- 
nated IV-HI) promoted significant levels of both adhesion 
and spreading. This peptide promoted melanoma cell adhe- 
sion in a concentration-dependent manner within a coating 
range of 1-500 t~g/ml (Fig.  1 a).  Significant cell adhesion 
(~35 % of input cells) occurred at a coating concentration 
of 10 ~g/ml of peptide IV-H1  and maximal cell adhesion 
(>50 % of input cells) was observed in wells coated with a 
100/xg/ml solution of peptide IV-H1.  The other peptides 
studied did not promote significant levels  of cell adhesion 
(<10% over BSA controls), even at the highest concentration 
of peptide studied (500/~g/ml). 
Melanoma cell spreading also occurred on surfaces coated 
with peptide IV-HI  in a concentration-dependent manner. 
Maximal  spreading  ('~70%  of input cells)  was  observed 
within 40 min at the 200 ~g/ml coating concentration of  pep- 
tide IV-HI (Fig.  1 b).  The other type IV collagen-derived 
peptides  promoted insignificant melanoma cell  spreading 
within the time frame studied. 
To ensure that peptide IV-HI-mediated cell adhesion and 
spreading was not unique to these melanoma cells, various 
other cell types were screened for adhesion and spreading on 
surfaces  coated  with  the  peptide.  Cells  of different em- 
bryonic origin and from various species were studied for the 
ability to adhere and spread on surfaces coated with peptide 
IV-H1.  The cell types comprise three major groups (Table 
II): (Group 1) cells that adhered and spread on both peptide 
IV-H1 and type IV collagen which, in addition to including 
the high metastatic murine K1735 M4 melanoma, included 
a highly metastatic human melanoma (A375 M), a rat glioma 
(C6), and a rat neuroblastoma (B104);  (Group 2) cells that 
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Figure 2. Melanoma cell motility in response to peptide IV-H1. In- 
creasing concentrations of peptide IV-H1 were used to coat poly- 
carbonate filters as described in Materials and Methods. Cells were 
added to the upper wells of a chamber containing the precoated 
filter. The number of cells that migrated was quantitated using an 
image analysis system. Data are presented as the average number 
of cells per square millimeter of filters coated with peptide IV-HI 
(o) or BSA (e). All data represent the means of at least three ex- 
periments in which triplicate determinations were made +  SEM. 
adhered and spread on type IV collagen but not on peptide 
IV-H1, including bovine aortic endothelial cells and the hu- 
man squamous carcinoma cell line (SCC9); and (Group 3) 
ceils that did not adhere to either type IV collagen or peptide 
IV-HI, including the murine UV2237 MM fibrosarcoma and 
the rat B65 neuroblastoma. In all cases, cell adhesion and 
spreading on surfaces coated with BSA or control peptides 
was <5 %. 
Melanoma Cell Motility on Peptide IV-ttl 
In light of the involvement of cell adhesion and spreading in 
motility (see Chelberg eta[., 1989), peptide IV-HI was stud- 
ied for its ability to directly promote melanoma cell motility. 
Peptide IV-H1 promoted a concentration-dependent increase 
in  melanoma cell motility in  microchemotaxis chambers 
(Fig. 2). Whereas a significant level of motility (twice BSA 
control levels) was observed at a coating level as low as 20 
#g/ml, maximal cell motility (5 x  BSA control levels)  was 
observed when the filter was coated with a  100-200 #g/ml 
solution of peptide IV-H1.  This compares with melanoma 
cell motility of 10-fold background levels in response to a 10 
#g/ml  solution  of intact  type IV  collagen as  previously 
reported (Chelberg et al.,  1989). 
Inhibition of Cellular Adhesion, Spreading, and 
Motility by Exogenous Peptide IV-H1 
Since peptide IV-H1 was observed to promote cell adhesion, 
spreading, and motility, it was necessary to demonstrate the 
activity of the IV-H1 sequence within the intact type IV col- 
lagen molecule. Thus, studies were performed to determine 
the ability of  the peptide to inhibit type IV collagen-mediated 
M4 melanoma cell adhesion, spreading, and migration. The 
specificity of the peptide IV-H1 sequence within type IV col- 
lagen was determined by including type I collagen and FN 
in the inhibition studies. As additional controls, two other 
peptides, type IV collagen peptide 17 and FN peptide I, were 
studied for the ability to inhibit collagen-mediated cell activ- 
ity. Cells remained viable in the presence of all concentra- 
tions of peptides studied, as demonstrated by exclusion of 
trypan blue dye (data not shown). 
In the adhesion assays, exogenous soluble peptide IV-H1 
strongly inhibited IV-H1  and  type IV  collagen-mediated 
melanoma cell adhesion (Fig. 3 a). Melanoma cell adhesion 
on  surfaces  coated with peptide  IV-HI  was  inhibited by 
nearly 40% in the presence of soluble peptide IV-H1  at 20 
t~g/ml, and by '~80% at the highest concentration of peptide 
IV-H1  tested (500 #g/ml). Similarly, melanoma cell adhe- 
sion to surfaces coated with type IV collagen was inhibited 
by ,,o20 % in the presence of only 20 #g/ml soluble peptide 
IV-HI, and by as much as 70 % at the highest concentration 
of peptide studied (500 #g/ml). In contrast, melanoma cell 
adhesion on surfaces coated with type I collagen was not 
affected by the presence of soluble peptide IV-HI. In addi- 
tion, no effect of the control peptide 17 (Fig. 3 a) or the FN 
peptide I  (data not shown) on type IV collagen-mediated 
melanoma cell adhesion was observed, even at the highest 
concentration tested (500 #g/ml). In all cases using type IV 
collagen-derived peptides, no inhibition of adhesion was ob- 
served on surfaces coated with FN, whereas peptide I spe- 
cifically inhibited FN-mediated adhesion (data not shown). 
Since soluble peptide IV-H1  inhibited type IV collagen- 
mediated melanoma cell adhesion, its effect on cell spread- 
ing was next studied. Cell spreading on surfaces coated with 
peptide IV-H1  was inhibited by up to 70% in the presence 
of soluble peptide IV-HI at 200 #g/ml (Fig. 3 b). Similarly, 
cell spreading on type IV collagen-coated surfaces was in- 
hibited by 20%  at the  100 #g/ml concentration of peptide 
IV-H1  and the level of cell spreading decreased by ,050% 
at the highest concentration studied (200 #g/ml). In contrast, 
pretreatment of cells with peptide IV-HI had no effect on the 
percent of cells spreading on surfaces coated with type I col- 
lagen. In control studies, excess peptide 17 (Fig. 3 b) or the 
FN peptide I (data not shown) had no effect on cell spreading 
on surfaces coated with type IV collagen or peptide IV-H1. 
In all cases using type IV collagen-derived peptides, no inhi- 
bition of FN-mediated spreading was observed, whereas the 
FN peptide I specifically inhibited FN-mediated spreading 
(data not shown). 
Finally, type IV collagen-mediated haptotactic melanoma 
cell motility was studied in the presence of  the synthetic pep- 
tides. Type IV collagen-mediated cell motility was inhibited 
by peptide IV-H1 in a dose-dependent manner with maximal 
inhibition of ,o80% at the 50/~g/ml level of peptide IV-H1 
(Fig. 3 c). Melanoma cell motility through filters precoated 
with type I collagen, however, was not inhibited by the pres- 
ence of peptide IV-H1.  Peptide 17 had no effect on type IV 
collagen-mediated cell motility. In additional control experi- 
ments, the FN peptide I specifically inhibited FN-mediated 
motility, whereas no inhibition was observed using type IV 
collagen-derived peptides (data not shown). 
Polyclonal  IgG Inhibition of ~pe IV 
Collagen-mediated Cell Adhesion, Spreading, 
and Motility 
Additional studies were designed to confirm the activity of 
the IV-H1 sequence within intact type IV collagen. In these 
studies, polyclonal antibodies were generated against pep- 
Chelberg eta|. A Novel Cell Binding Region in Type IV Collagen  265 120 
100 
~  6o 
~  4o 
0 
a 
0  100  200  300  400  500 
Peptlde  Concentration  (~g/ml) 
Table IlL Reactivity of  Antibody Raised against 
Peptide IV-HI 
]gG Concentration (#g/ml) 
Protein or peptide 
(ligand)  0.001 *  0.004  0.02  1.0 
Peptide IV-H1  2,996~  3,179  3,705  3,927 
Type IV collagen  127  290  779  1,747 
Type I  collagen  69  71  110  198 
Fibronectin  88  73  88  257 
* Purified antipeptide  IV-H1 IgG was screened for specificity  by an indirect 
solid-phase RIA.  Briefly,  surfaces were coated with proteins or peptides as 
described in Materials and Methods. Purified IgG at various dilutions were 
added. Bound IgG was detected by the addition of uSI-labeled secondary IgG 
(sp act, 5 ~Ci/~g). 
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Figure 3.  Inhibition of adhesion,  spreading, and motility on type 
IV collagen by peptide  IV-H1. 3H-Thymidine-labeled M4 mela- 
noma cells were preincubated  with  increasing concentrations  of 
soluble  peptides  and  cell  adhesion  or spreading  on peptide-  or 
protein-coated surfaces was determined in the continued presence 
of the peptides. Cell adhesion (a) or spreading (b) in the presence 
of soluble peptide IV-HI was determined on surfaces coated with 
5/~g/ml type IV collagen (m) or type I collagen (t3), or 50 #g/ml 
peptide IV-H1 (o); or in the presence of peptide  17 on surfaces 
coated with 5 #g/ml type IV collagen (e). Data are presented as 
the percent of cells adherent or spread in the presence of peptide 
relative to adhesion/spreading in the absence of soluble peptide. (c) 
Filters were coated on the underside with either type IV collagen 
or type I collagen as described  in Materials  and  Methods.  Cell 
migration was quantitated in the presence of soluble peptide IV-HI 
tide  IV-H1  and  tested  for  the  ability  to  inhibit  type  IV 
collagen-mediated M4 melanoma cell adhesion,  spreading, 
and motility. Purified IgG generated against KLH-coupled 
peptide IV-HI was screened for immunoreactivity by RIA 
(Table III). Reactivity of antipeptide IV-HI IgG was type IV 
collagen-specific, since the IgG recognized type IV collagen 
and peptide IV-H1 but not type I collagen or FN. The con- 
trois, purified normal rabbit IgG or purified IgG generated 
against the FN peptide I coupled to KLH did not react with 
type IV collagen or any of the synthetic type IV collagen-de- 
rived  peptides,  although  antipeptide  I  IgG  specifically 
reacted with FN (data not shown). 
Melanoma cell adhesion on surfaces coated with peptide 
IV-H1, intact type IV collagen, or type I collagen was moni- 
tored in the presence of increasing concentrations of antipep- 
tide IV-H1 IgG. Melanoma cell adhesion on surfaces coated 
with  50  /~g/ml  of peptide IV-H1  was inhibited  ,~40%  by 
anti-IV-H1 IgG at 20/~g/ml (Fig. 4 a). Maximal inhibition 
(70 %) was observed at the highest concentration of antibody 
tested (500/~g/ml).  Cell adhesion to type IV collagen was 
also reduced in a concentration-dependent manner by prein- 
cubation with anti-IV-H1 IgG. Significant inhibition (20%) 
was observed in the presence of only 20 #g/ml of antipeptide 
IV-H1 IgG, and a 40% inhibition of adhesion was observed 
at 500/zg/ml of antipeptide IV-H1 IgG. In contrast, preincu- 
bation with the antipeptide IV-H1 IgG did not reduce the lev- 
els of melanoma cell adhesion to surfaces coated with type 
I collagen. No inhibition of cell adhesion to surfaces coated 
with any of the collagenous proteins was observed in the 
presence of normal rabbit IgG or anti-FN peptide I IgG, even 
at the highest concentration used (500 #g/ml); demonstrated 
by the lack of inhibition of cell adhesion to peptide IV-H1 
with normal rabbit IgG (Fig. 4 a). As expected, antipeptide 
I IgG reduced cell adhesion to FN by up to 60%  (data not 
shown). 
Melanoma cell spreading on surfaces coated with peptide 
IV-H1, intact type IV collagen, or type I collagen was moni- 
using filters coated with type IV collagen (m) or type I collagen 
([]), or in the presence of soluble peptide  17 using filters coated 
with type IV collagen (a). All data represent the means of at least 
three experiments  in which  triplicate  determinations  were made 
+  SEM. 
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Figure 4.  Anti-IV-HI  IgG inhibition of melanoma cell adhesion, 
spreading,  and motility on type IV collagen. (a) Immulon I plates 
were coated,  as described in Materials and Methods, with peptide 
IV-HI, type IV collagen, or type I collagen (50/.tg/ml,  5 yg/ml, 
and 5/~g/ml, respectively). Coated surfaces were preincubated with 
increasing concentrations of anti-IV-H1 [gG or normal rabbit IgG, 
then cells were added in the continued presence of IgG. Data are 
presented as the percent of cells adherent in the presence of antipep- 
tide IV-H1 IgG on surfaces coated with type IV collagen (I), type 
I collagen (o), or peptide IV-H1 (o), or in the presence of normal 
rabbit IgG on type IV collagen (zx). (b)  Assay proceeded as in a. 
Data are presented as the percent of cells spreading in the presence 
of antipeptide IV-H1 IgG on surfaces coated with type IV collagen 
(I), type I collagen (o), or peptide IV-HI  (o), or in the presence 
of normal rabbit IgG on type IV collagen (zx). Data are expressed 
tored in the presence of increasing concentrations of anti- 
peptide IV-HI IgG. Cell spreading on surfaces coated with 
peptide IV-HI was significantly decreased (50%) at levels of 
antipeptide IV-H1 IgG as low as 20/~g/ml, and maximal in- 
hibition (80%) was observed at 50 #g/ml (Fig. 4 b).  Simi- 
larly, cell spreading on surfaces coated with type IV collagen 
was decreased by 20%  in the presence of 50 #g/ml of an- 
tipeptide IV-HI IgG and by as much as 60% when 100/zg/ml 
of this IgG was present. In contrast, cell spreading on sur- 
faces coated with type I collagen was not affected by this IgG 
(Fig. 4 b). The controls, normal rabbit IgG and antipeptide I 
IgG, did not affect cell spreading on surfaces coated with 
peptide IV-H1,  type IV collagen, or type I collagen. 
The effect of  antipeptide IV-HI IgG on melanoma cell hap- 
totaxis mediated by type IV collagen was monitored by in- 
cubating the collagen-coated filter with antipeptide IV-HI 
IgG before the addition of cells to the motility assay (Fig. 
4 c).  Motility was decreased in a concentration-dependent 
manner with maximal inhibition of  70 % at 100/~g/ml of  IgG. 
In contrast, cell motility through filters precoated with type 
I collagen (Fig. 4 c) or FN (data not shown) was not inhibited 
by preincubation of the filters with antipeptide IV-H1  IgG. 
Normal rabbit IgG had no effect on type IV collagen-medi- 
ated cell motility. 
Melanoma Cell Adhesion, Spreading, and Motility on 
Alanyl-substituted Peptide IV-H1 
In light of the reported importance of prolyl residues  in 
mediating cell adhesion on collagen-coated surfaces (Rubin 
et al., 1981), a substituted version of peptide IV-HI was syn- 
thesized to determine the relative importance of these resi- 
dues in the ability of peptide IV-HI  to promote M4 mela- 
noma cell adhesion,  spreading, and motility. This peptide, 
designated IV-H1A,  contained alanyl residues (A) in place 
of the three prolyl residues of the IV-HI sequence (GVKG- 
DKGNAGWAGAA). Melanoma cell adhesion was essen- 
tially unaffected by the alanyl-substitution of peptide IV-H1, 
since cells adhered to nearly the same extent on surfaces 
coated with either peptide IV-H1 or IV-H1A (Fig. 5). How- 
ever, ceils exhibited a substantially decreased ability to spread 
on surfaces coated with peptide IV-H1A compared to spread- 
ing on peptide IV-H1 (Fig. 6). This occurred at all concen- 
trations of the peptides (5-500 #g/ml) and at all time points 
monitored (20-90 min). Studies in which these two peptides 
were radiolabeled and bound to the plates indicated that pep- 
as the percent of cell adhesion/spreading in the presence of IgG, rel- 
ative to adhesion/spreading  in the absence of IgG (represented as 
the 0 concentration).  (c) Polycarbonate filters were coated on the 
underside with either type IV collagen or type I collagen, as de- 
scribed in Materials and Methods.  Antipeptide IV-HI or normal 
rabbit IgG was added to the lower wells of the motility chambers 
in increasing concentrations and allowed to bind to the coated filters 
for 30 min.  Cell motility was quantitated  after a 4-h incubation. 
Data are presented as the average number of cells per square mil- 
limeter of filters coated with type IV collagen (I) or type I colla- 
gen (o)  in the presence of antipeptide IV-H1  IgG; or on type IV 
collagen in the presence of normal rabbit lgG (zx). All data repre- 
sent the means of at least three experiments in which triplicate de- 
terminations were made  +  SEM. 
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Figure 5. Adhesion of melanoma cells on alanyl-substituted peptide 
IV-HI. Peptide IV-HI (o) or peptide IV-HIA (e) were coated to 
wells as described  in Materials  and Methods.  Cell adhesion data 
are presented as the percent of ceils added that were adherent.  All 
data represent  the means of at least three  experiments  in which 
triplicate  determinations  were made  +  SEM. 
tide IV-H1A binds to the plates as well as or better than na- 
tive peptide IV-H1 at all concentrations tested (Table IV). 
These findings indicate that the reduced spreading of cells 
that was observed on surfaces coated with peptide IV-H1A 
was not due simply to failure of this peptide to bind to the 
plates. 
In addition to decreasing the ability of peptide IV-H1 to 
promote melanoma cell spreading,  the alanyl substitutions 
also decreased the ability of peptide IV-HI to promote mela- 
noma cell motility. Cell motility was not observed through 
filters coated with peptide IV-H1A, even at the highest con- 
centrations  tested (Fig.  7),  whereas peptide IV-HI-coated 
filters promoted significant cell motility at levels as low as 
10 #g/ml. The relative abilities of the peptides to bind to the 
filters was determined using radioiodinated peptides to be 
certain  that  the  differences  in  motility  were  not  due  to 
differential binding of the peptides to the filters. The studies 
demonstrated that peptide IV-H1A and peptide IV-HI bound 
to the filters to similar extents (Table IV). 
Table IV. Relative Binding of  Peptides to Surfaces 
Polystyrene plates~:  Polycarbonate  filters§ 
(ug/well)  Qag/well) 
Peptide*  Input  Bound  Input  Bound 
IV-H1 
IV-H1A 
0.1  0.094  1.75  0.020 
0.5  0.130  3.5  0.052 
1.0  0.364  7.0  0.221 
0.1  0.120  1.75  0.005 
0.5  0.420  3.5  0.071 
1.0  0.479  7.0  0.196 
* The relative abilities of the peptides to bind to the plates or filters were deter- 
mined using radioiodinated peptides. Radioiodinated peptides were dried to the 
plastic plates (100 #l/well  at each concentration) or polycarbonate filters (35 
tA/well at each concentration) as described  in Materials and Methods. 
~: Using  a  specific activity  of 4.4  ×  l0  s or  1.1  ×  l0  s cpnd/~g for peptide 
IV-HI or IV-H1A, respectively, the amount of label bound per well was con- 
verted to/~g/well  bound. 
§ Using a  specific activity  of 1.3  ×  106  or  1.1  ×  106  cpm//~g for peptide 
IV-HI or IV-HIA, respectively,  the amount of label bound to the filter per 
well was converted to ~g/well bound. 
Discussion 
A growing body of evidence, including the identification of 
type IV collagen-specific integrin-like receptors on the sur- 
face  of tumor  cells  (Tomaselli et  al.,  1988;  Kramer and 
Marks,  1989) indicates that BM type IV collagen may play 
a major role in tumor cell invasion of BM. Cell adhesion and 
motility on BM components have been described as neces- 
sary steps in BM invasion (Liotta, 1977). Our earlier studies 
(Chelberg et al., 1989) presented data that indicated that cell 
adhesion and spreading on surfaces coated with type IV col- 
lagen involve multiple,  distinct  domains  of the  molecule. 
Whereas  both the  purified  helical p-IV fragment and  the 
NC1 domain of type IV collagen supported in vitro M4 mela- 
noma cell adhesion and spreading, only the p-IV fragment 
promoted cell motility.  In addition,  our findings  indicated 
that these cell activities (adhesion and spreading) are neces- 
sary,  albeit insufficient,  for successful cell motility.  Since 
cell motility is instrumental in tumor cell invasion of BM, 
the triple helical portion of type IV collagen has become a 
major focus of our further investigation. The current studies 
Figure 6. Spreading of melanoma cells on native peptide IV-HI and alanyl-substituted peptide IV-H1A. BSA (A), peptide IV-H1A (B), 
or peptide IV-HI (C) were coated to wells as described  in Materials and Methods and M4 melanoma cell spreading was monitored  for 
80 min.  The photomicrographs  demonstrate  the portion of adherent cells that were spread at 80 rain.  Bar, 50/~m. 
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Figure 7. Directiona] motility of me]anoma cel]s in response to the 
alanyl-substituted  peptide IV-HI. Polycarbonate  filters were coated 
as described in Materials and Methods with peptide IV-H1 (o) or 
peptide IV-HIA (o). Cell motility in response to these peptides was 
quantitated by image analysis microscopy. All data represent the 
means of at least three experiments in which triplicate determina- 
tions were made +  SEM. 
have been designed to further understand the molecular ba- 
sis of  the cellular responses promoted by the p-IV fragments. 
To this end, several synthetic peptides, derived from the od 
chain of  the major triple helical region of  human type IV col- 
lagen,  have been screened for the ability to promote cell 
adhesion and spreading. 
The present studies indicate that a type IV collagen-de- 
rived sequence, designated peptide IV-H1, represents a cell 
adhesion, spreading, and motility promoting domain within 
the type IV collagen molecule. This is supported in part by 
the observations that peptide IV-H1 promoted these cellular 
activities in a  concentration-dependent manner in  studies 
using the highly metastatic M4 melanoma cell line. In addi- 
tion, peptide IV-H1, or a polyclonal antibody directed against 
peptide IV-H1,  inhibited type IV collagen-mediated mela- 
noma cell adhesion, spreading, and motility. The latter re- 
sults indicate that the sequence represented by peptide IV-HI 
is active within the intact type IV collagen molecule. 
Current studies have demonstrated receptors that recog- 
nize both type IV and either native type I collagen or gelatin 
(Kurkinen et al., 1984;  Sugrue, 1987; Kramer and Marks, 
1989). However, the findings presented here indicate that the 
effects of the peptide IV-H1 sequence are specific to type IV 
collagen. This is supported, in part, by our observations that 
type I collagen-mediated melanoma cell adhesion, spread- 
ing, and motility were not affected in competition studies by 
peptide IV-H1  or antipeptide IV-HI IgG, and is consistent 
with the observed absence of a IV-HI-like sequence within 
type I collagen in computer searches (using the ALLIGN op- 
tion of the PEP software or the QUEST program of the Intel- 
ligenetics Software package). It will be necessary, in future 
studies, to isolate a cell surface receptor that recognizes the 
sequence of peptide IV-H1  to test this hypothesis directly. 
Studies of the adhesion and spreading of various normal 
and tumor cell types to surfaces coated with type IV collagen 
or peptide IV-H1 support a cell type-specific interaction with 
the IV-H1  sequence. In addition to the murine K1735  M4 
melanoma cell line, cell lines derived from a human mela- 
noma, a rat glioma, and a rat neuroblastoma were all ob- 
served  to  adhere and  spread  extremely well  on  surfaces 
coated with the human-derived peptide IV-H1.  These find- 
ings support the possibility that the activity of the IV-H1 se- 
quence in type IV collagen is conserved across species. This 
may be expected since the amino acid sequence of the entire 
type IV collagen molecule is highly conserved between the 
human and murine species (Muthukamaran et al., 1989).  It 
will be of interest to further define the minimal sequence 
within peptide IV-H1  that supports  cellular adhesion and 
motility, and to determine the sequence homology across 
species of this determinant. 
Cell type specificity of peptide IV-HI-mediated cell adhe- 
sion and spreading was demonstrated by other cell types that 
strongly adhere to surfaces coated with type IV collagen, but 
which exhibited no adhesion to surfaces coated with peptide 
IV-H1. These cell types are represented in the current studies 
by the human squamous carcinoma cell line and bovine aor- 
tic endothelial cells. These observations suggest that differ- 
ent mechanisms for cell adhesion and spreading on type IV 
collagen may be used by different  cell types. Additional cells, 
including a  fibrosarcoma and neuroblastoma cell line, did 
not adhere to either intact type IV collagen or peptide IV-H1. 
It is worth noting that no cells were found to adhere to pep- 
tide IV-HI which also did not adhere to intact type IV colla- 
gen. Taken with the results of the inhibition studies, this ob- 
servation supports our assumption that the activity of  peptide 
IV-H1  was not created upon removal of the sequence from 
the context of the intact type IV collagen molecule. 
A peptide was synthesized, designated IV-H1A, in which 
alanyl residues were substituted for the three prolyl residues 
within  the  IV-H1  sequence,  to  confirm  that  the  prolyl 
residues alone were not responsible for the activity of pep- 
tide IV-H1. Previous studies by Rubin et al. (1981) indicated 
that multiple prolyl residues presented in the coUagenous he- 
lical motif promoted hepatocyte adhesion. In their studies, 
the tripeptide gly-X-pro  repeat sequence promoted signifi- 
cant levels of adhesion, although reduced relative to intact 
collagens of various types or the cyanogen bromide-derived 
fragments of type I collagen. The conservative substitutions 
of alanyl residues for prolyl residues in the present studies 
drastically decreased the spreading and motility promoting 
activities of peptide IV-HIA relative to the parent IV-H1. 
These observations suggest that the prolyl residues are cru- 
cial for maintenance of the full repertoire of functions of the 
active sites within peptide IV-H1, in agreement with the find- 
ings of Rubin et al. (1981). Melanoma cell adhesion, how- 
ever, was not affected by the amino acid substitutions. Taken 
together, these observations indicate that conservation of the 
prolyl residues is crucial for the full complement of IV-HI 
sequence activities, but that other factors within peptide IV-H1 
are also involved in promoting cell attachment. Although we 
do not presently have an explanation for these observations, 
the collagenous helix would be predicted to be more closed 
(<3.2 A/turn) in the absence of the prolyl residues, which 
would alter the conformation of an active site.  Additional 
studies are currently being performed to further establish the 
active site within peptide IV-H1. These studies, in combina- 
tion with the isolation of a receptor(s) recognizing this se- 
quence, will shed new light on the molecular basis of type 
IV collagen-mediated cell adhesion, spreading, and motility. 
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